Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NP432 is a synthetic linear peptide antibacterial drug candidate developed by NovaBiotics. It belongs to a novel class of immune-based antimicrobials designed to combat multi-drug resistant bacterial infections. The peptide is approximately 2 kDa in size and comprises both polar and nonpolar aromatic residues. Its mechanism of action involves enhancing cell membrane permeability in bacteria, leading to rapid bactericidal activity. Notably, it demonstrates efficacy against Gram-negative bacteria such as Acinetobacter baumannii and some Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Unlike traditional antibiotics, its activity is agnostic to the metabolic or drug-resistance status of the target pathogen and aims to circumvent off-target pharmacology[1][2][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NP432.